Newly emerging standard chemotherapies for gastric cancer and clinical potential in elderly patients

doi:10.4251/wjgo.v1.i1.47

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 1, Issue 1

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4752)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-3) series.

Item

Count

PDF

495

HTML

3303

Figures (1-1)

509

Tables (1-3)

445

Sum=4752

Oct 15, 2009 (publication date) through Nov 21, 2024

Times Cited of This Article

Times Cited (5)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Gastrointest Oncol. Oct 15, 2009; 1(1): 47-54
Published online Oct 15, 2009. doi: 10.4251/wjgo.v1.i1.47

Table 2 Phase III milestone trials of chemotherapy for far advanced gastric cancer and information of the elderly patients

Publication	Trial	Regimens	OS (number)	Selected regimens	Median	Age range	Proportion of elderly patients (70 years old or over)	Ref.	Country
1991	EORTC	5-FU/Adriamycin/MMC (FAM)	4 (79)	FAMTX	58	23-69	No information	[7]	EORTC
1991	EORTC	5-FU/Adriamycin/Methotrexate (FAMTX)	6 (81)		57	28-77
1993	Murad et al	FAMTX	9 (30)	FAMTX	58	26-72	No information	[3]	Brazil
1993	Murad et al	Best supportive care (BSC)	3 (10)		57	30-71
1995	Pyrhönen et al	5-FU/Epirubicin/Methotrexate (FEMTX)	12.3 (21)	FEMTX	58	42-75	No information	[5]	Finland
1995	Pyrhönen et al	BSC	3.1 (20)		58	42-71
1997	Glimelius et al	5-FU/Leucovorin/Etoposide (FLE)	8 (31)	ELF	64	45-75	No information	[4]	Sweden
1997	Glimelius et al	BSC	5 (31)		63	40-74
1997	Webb et al	EPI/CDDP/5-FU (ECF)	8.9 (111)	ECF	59	35-79	No information	[8]	UK
1997	Webb et al	FAMTX	5.7 (108)		60	29-78
2000	Vanhoefer et al	FAMTX	6.7 (133)	Similar efficacy	58	30-74	No information	[44]	EORTC
		ELF	7.2 (132)		59	25-74
		5-FU/CDDP (FUP)	7.2 (134)		57	24-74
2003	JCOG9205	5-FU	7.1 (105)	5-FU	63	27-75	No information	[14]	Japan
		5-FU/CDDP (CF)	7.3 (105)		63	19-75
		UFT/MMC	6 (70)		60.5	30-75
2006	V325	Docetaxel/CDDP/5-FU (DCF)	9.2 (227)	DCF	55	26-79	24%-25%¹	[10]	USA
2006	V325	CDDP/5-FU (CF)	8.6 (230)		55	25-76
2007	JCOG9912	S1	11.4 (234)	S1	64	39-75	No information	[17]	Japan
		5-FU	10.8 (234)		63	24-75
		CPT11/Docetaxel	12.3 (236)		63	32-75
2008	SPIRITS	S1	11 (150)	S1/CDDP	62	28-74	17%	[18]	Japan
2008	SPIRITS	S1/CDDP (CS)	13 (148)		62	33-74
2008	REAL-2	EPI/CDDP/capecitabine (ECX)	9.9 (241)	EOX	64	25-82	No information	[9]	UK
		ECF	9.9 (249)		65	22-83
		EPI/oxaliplatin/capecitabine (EOX)	11.2 (239)		62	25-80
		EPI/oxaliplatin/5-FU (EOF)	9.3 (235)		61	33-78
2008	Al-Batran et al	5-FU/LV/Oxaliplatin (FLO)	10.7 (112)	FLO	64	33-86	41%-45%²	[23]	AIO
2008	Al-Batran et al	5-FU/LV/CDDP (FLP)	8.8 (108)		64	27-85

¹This is proportion of patients with 65 years old or over;

²This is proportion of patients over 65 years old.

Citation: Sakuramoto S, Yamashita K, Watanabe M. Newly emerging standard chemotherapies for gastric cancer and clinical potential in elderly patients. World J Gastrointest Oncol 2009; 1(1): 47-54
URL: https://www.wjgnet.com/1948-5204/full/v1/i1/47.htm
DOI: https://dx.doi.org/10.4251/wjgo.v1.i1.47